In the NIBIT-M1 study, the authors reported a promising activity of ipilimumab combined with fotemustine in metastatic melanoma (MM) patients with or without brain metastases. To corroborate these initial findings, they now investigated the long-term efficacy of this combination.

READ FULL ARTICLE Curated publisher From Mdlinx